Hemispherx Biopharma (HEB) 0.22 $HEB Hemispherx

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Hemispherx Biopharma (HEB) 0.22 $HEB

Hemispherx Biopharma FY14 results
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 8:52AM CDT

HEB: 0.22 (-0.01)

Hemispherx Biopharma reports FY2014 results
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 8:37AM CDT

HEB: 0.22 (-0.01)

Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2014
GlobeNewswire - Fri Mar 20, 8:28AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the year ended December 31, 2014. The net loss (including non-cash effects) was approximately $17,450,000 or $(0.09) per share as compared to a net loss of $16,225,000 or ($0.10) per share for the same twelve month period in 2013. Cash, cash equivalents and marketable securities were approximately $16,108,000 at December 31, 2014 as compared to $18,194,000 as of December 31, 2013.
HEB: 0.22 (-0.01)

Hemispherx Uses Ebola Tragedy to Raise Cash, Pay Executive Bonuses
at The Street - Tue Mar 10, 10:10AM CDT
Since the end of September, Hemispherx sold almost 25 million shares of company stock, equivalent to the amount of stock sold in the first nine months of 2014.
VRTX: 131.00 (-3.25), SGEN: 38.86 (-0.83), HEB: 0.22 (-0.01)

Hemispherx Enters a Collaboration with Emerge Health for the Commercialization of Ampligen for Chronic Fatigue Syndrome (CFS) in Australia and New Zealand
GlobeNewswire - Mon Mar 09, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , reported today that it has executed an agreement with Emerge Health Pty Ltd. ("Emerge" to seek approval of Ampligen, an experimental immunotherapeutic, for Chronic Fatigue Syndrome in Australia and New Zealand and to commence distribution of Ampligen in both countries on a named-patient basis, where deemed appropriate.
HEB: 0.22 (-0.01)

Regulators Want Drug Companies to Be Honest About FDA
at The Street - Wed Mar 04, 12:08PM CST
The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.
HEB: 0.22 (-0.01), AVEO: 1.35 (-0.16), AMPE: 8.52 (+0.08), SNY: 50.64 (+1.17)

Hemispherx Biopharma Announces the Completion of the Newly Upgraded Alferon(R) Facility: Commercial Production of Alferon(R) is in the Final Stage Integrating Continuous Flow Manufacturing Technology
GlobeNewswire - Mon Mar 02, 7:30AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" announced today that its manufacturing site located in New Brunswick, New Jersey, presently configured at over 43,000 square feet, has completed its $8 million of upgrades. These upgrades will provide for a higher capacity, more cost effective manufacturing process for the production of Alferon N Injection(R), the only FDA-approved natural alpha interferon. The added efficiency of the process has been accomplished by integrating continuous flow manufacturing technology throughout the process. This has led to improved cost efficiency, enhanced yields, real-time process monitoring, flexibility to tailor batch size for lean manufacturing, and improved operational safety as seen in other cutting edge pharmaceutical companies.
HEB: 0.22 (-0.01)

Biotech Weekly: 5 Factors Contributing To The Crazy Week That Was In Small Cap Biotech
Daniel Ward - at Seeking Alpha - Mon Feb 23, 7:40AM CST

HEB: 0.22 (-0.01), XBI: 233.86 (-4.12), IBIO: 0.79 (+0.02), IBB: 366.52 (+1.27), SPPI: 6.17 (-0.24), CLTX: 0.85 (+0.02)

WHO approves rapid test for Ebola
Seeking Alpha - at Seeking Alpha - Fri Feb 20, 6:15AM CST

BCRX: 9.49 (-0.74), TKMR: 19.48 (-1.01), GSK: 48.81 (+0.60), INO: 9.09 (-0.36), JNJ: 102.40 (+0.71), CMRX: 40.61 (-1.50), NVAX: 9.58 (-0.13), HEB: 0.22 (-0.01), MRK: 58.58 (+0.37), SRPT: 13.16 (-0.76), NLNK: 54.57 (-1.36), ABIO: 0.82 (-0.01), IBIO: 0.79 (+0.02)

What's New in the Biotechnology Sector: Special Research on Vical,Asterias, Bacterin, Hemispherx BioPharma, and IGI Laboratories
PR Newswire - Thu Feb 19, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
VICL: 0.97 (+0.01), BONE: 4.20 (-0.04), HEB: 0.22 (-0.01), AST: 7.88 (-0.40), IG: 9.32 (+0.65)

Hemispherx Biopharma and USAMRIID to Present New Discoveries Concerning the Efficacy of Ampligen(R) Against the Ebola Virus at Upcoming International Symposium on Filoviruses
GlobeNewswire - Thu Feb 12, 7:30AM CST
Ampligen(R) May Be an Important Candidate for EBOV Testing in West Africa
HEB: 0.22 (-0.01)

U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST

INO: 9.09 (-0.36), JNJ: 102.40 (+0.71), BCRX: 9.49 (-0.74), HEB: 0.22 (-0.01), NLNK: 54.57 (-1.36), TKMR: 19.48 (-1.01), NNVC: 2.58 (-0.14), GSK: 48.81 (+0.60)

Hemispherx Biopharma Posts USAMRIID Ebola Study Concluding Ampligen(R) Produced 100% Survival Rate in Rodents With 100% Mortality in Placebo
GlobeNewswire - Mon Feb 09, 7:30AM CST
Based upon numerous Hemispherx stockholder requests, Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" has posted the report and findings of the recent efficacy study of Ampligen(R) in a mouse model of Ebola virus infection performed by scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID). The posted USAMRIID report conclusively refutes false and defamatory blog and online statements by TheStreet.com's blogger Adam Feuerstein and invalidates Feuerstein's negative social media postings about the company's press release that was issued on February 2, 2015.
HEB: 0.22 (-0.01)

Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx
at The Street - Fri Feb 06, 5:05AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BLUE: 124.76 (-1.64), ADXS: 12.54 (+0.14), GILD: 102.29 (+0.85), HEB: 0.22 (-0.01), ACHN: 11.06 (-0.36), MRK: 58.58 (+0.37), ABBV: 60.40 (-0.79)

U.S. Army Medical Researchers to Hemispherx: We're Really Not That Into You
at The Street - Wed Feb 04, 11:59AM CST
A spokeswoman for the U.S. Army Medical Research Institute says its testing of Alferon and Ampligen drugs for ebola is complete and the relationship has ended.
HEB: 0.22 (-0.01)

Hemispherx: U.S. Army Scientists (USAMRIID) Find Ampligen(R) Produces 100% Survival Rate in Ebola Virus Rodent Study
GlobeNewswire - Mon Feb 02, 9:05AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announced today the results of a new efficacy study of Ampligen(R) in a mouse model of Ebola virus (EBOV) infection performed by scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID).
HEB: 0.22 (-0.01)

USAMRIID Reports Genetic Changes in Ebola Virus May Impede Potential Treatments
GlobeNewswire - Mon Jan 26, 7:30AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announced today that in a new publication in the journal mBio, scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID), Harvard University, and Massachusetts Institute of Technology (MIT) studied genetic changes in the Ebola virus (EBOV) circulating in West Africa and concluded that genomic drift of the EBOV over time may be sufficient to block the action of otherwise potential therapies that target EBOV genetic sequences. The types of potential drugs at risk include monoclonal antibodies and small-interfering RNA (siRNA) which are scheduled to be evaluated during the current outbreak (see below). The USAMRIID press release states that "genetic drift must be considered when developing potential therapeutics, in order to ensure that changes in the Ebola virus over time do not render those treatments ineffective......the USAMRIID team compared the current strain, called EBOV/Mak, with the two previous strains that caused outbreaks in 1976 and 1995 in Zaire (now the Democratic Republic of the Congo). In each comparison, they found more than 600 genetic mutations. Next, the group focused on only the mutations that occurred in the genetic sequences targeted by the experimental therapeutics. Of these, they found 10 new mutations that might interfere with the mechanisms of the sequence-based drugs currently being tested. Three of these mutations appeared during the current West African outbreak." (http://www.usamriid.army.mil/newsroom.htm).
HEB: 0.22 (-0.01)

NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST

INO: 9.09 (-0.36), BCRX: 9.49 (-0.74), CMRX: 40.61 (-1.50), HEB: 0.22 (-0.01), SRPT: 13.16 (-0.76), ABIO: 0.82 (-0.01), TKMR: 19.48 (-1.01), NNVC: 2.58 (-0.14)

Hemispherx Biopharma Awarded $770,852 by Federal Judge
GlobeNewswire - Thu Jan 15, 7:59AM CST
Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx" announced that after prevailing in a federal lawsuit brought against the Company by Cato Capital, the United States District Court for the District of Delaware has ordered Cato to pay Hemispherx attorney's fees and costs in the amount of $770,852.76. Previously, in September 2014, the Court dismissed all claims brought by Cato against Hemispherx, including counts of breach of contract and fraudulent inducement--completely vindicating the Company of any wrongdoing.
HEB: 0.22 (-0.01)

Low Natural Killer (NK) Activity Observed Across the Chronic Fatigue Syndrome (CFS) Disease Spectrum
GlobeNewswire - Mon Jan 12, 8:16AM CST
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , reported today that it has conducted new in vitro studies of natural killer (NK) cells obtained from CFS patients in conjunction with a comprehensive review of the medical literature to determine the relative incidence of NK cell functional deficiencies in CFS disease. This review indicates that low NK cell cytotoxicity (NKCC) has been consistently reported in CFS patients compared to normal controls. In the new laboratory studies, Ampligen(R) (rintatolimod), an experimental therapeutic, was found to increase in vitro NK activity utilizing cells from CFS patient donors. The authors of the new report are all affiliated with Hemispherx.
HEB: 0.22 (-0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 187

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
NVIDIA Faces Turbulent Storm with CEO Resignation

Updated Category News Views 5

Huang's Unexpected Exit and NVIDIA's Rocky Road Well, talk about drama in Silicon Valley. When executives start stumbling, it's not just some PR nightmare—it's a full-on crisis. NVIDIA's co-founder and CEO Jensen Huang is calling it quits, and not on some smooth, idyllic note. No, this is the kind of exit that investors dread. You’ve got affairs, security concerns,...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 46

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 131

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Parallels Desktop Tops 2026 Picks for Windows on Mac

Updated Category News Views 59

Diving into the Cross-Platform Conundrum Now, I've been in the trenches long enough to know that when companies start relying on Mac computers but can't ditch their essential Windows apps, they're bound to hit a digital brick wall. Picture this—accounting, enterprise management, all that jazz that still needs Windows to function. For those jumping between these two...

Continue Reading
Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 0

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 35

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 67

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 117

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Plumas Bancorp Increases Shareholder Value with Dividend

Updated Category News Views 100

Plumas Bancorp Announces Quarterly Cash Dividend Plumas Bancorp (Nasdaq: PLBC), the parent company of Plumas Bank, has recently made an important announcement regarding its financial strategy. The Board of Directors has declared a regular quarterly cash dividend of $0.30 per share on common stock, as a testament to the company's ongoing commitment to delivering value to...

Continue Reading
DTE Energy's Junior Subordinated Debentures Offer: Key Insights

Updated Category News Views 168

DTE Energy's Junior Subordinated Debentures Introduction DTE Energy Company (NYSE: DTE) has made a significant announcement regarding its financial strategies through the pricing of its 2025 Series H 6.25% Junior Subordinated Debentures. This offering, valued at $600 million in aggregate principal, is designed for various financial maneuvers that could solidify DTE's...

Continue Reading
Key Insights on SCOR's Share Capital and Voting Rights Details

Updated Category News Views 294

Understanding SCOR's Recent Share Capital Declaration On a notable date, SCOR made a significant announcement regarding its share capital. The communication was essential for understanding the current status of total shares and voting rights. As a leading global reinsurer, SCOR's declarations provide crucial insights into its financial health and operational metrics....

Continue Reading
Enthusiast Gaming's Record-Breaking Spectacle at Luminosity Event

Updated Category News Views 100

Enthusiast Gaming's Luminosity Invitational Shines Bright Enthusiast Gaming Holdings Inc. ('Enthusiast Gaming' or the 'Company'), a dynamic leader in the gaming and media sector, has made waves recently with its spectacular Luminosity Invitational: Back 2 School. This thrilling Super Smash Bros Ultimate event drew in a staggering estimate of over 400,000 unique online...

Continue Reading
UAB Kvartalas Closes Subscription Early for Latest Bonds

Updated Category News Views 128

UAB Kvartalas Closes Subscription for 4th Tranche of Bonds UAB "Kvartalas", a legal entity committed to facilitating growth and innovation, has made a significant announcement regarding its bond issuance process. The company, registered with the legal code 305475438, has its headquarters situated at Jogailos St. 4, Vilnius, Republic of Lithuania. In response to...

Continue Reading